CSA Medical Announces Enrollment of First Patient into a Dedicated Esophageal Cancer Trial Using truFreeze® Rapid AV

BOSTON, Nov. 27, 2017 /PRNewswire/ -- CSA Medical is pleased to announce the enrollment of the first patient into a multi-center prospective study evaluating the effects of spray cryotherapy on patients suffering from esophageal cancer.

"We are excited to announce the first patient enrolled in this study evaluating truFreeze Rapid AV for the management of patients with esophageal cancer," said Ellen Sheets MD, CEO and President of CSA Medical.  "With the recent expansion of the truFreeze label and the release of the Rapid AV Catheter, we now have label indication to include the ablation of Barrett's Esophagus with high grade dysplasia and/or low grade dysplasia in addition to the ablation of malignant disease.  This provides physicians with the ability to ablate a variety of benign and malignant lesions in the esophagus with a single device."

The patient was treated at the University of North Carolina's Center for Esophageal Diseases and Swallowing.  "We are pleased to be part of this study examining the effects of cryotherapy on esophageal cancer, such as change in functional status and decreasing the size of local persistent or recurrent disease," said Dr. Nicholas J. Shaheen, MD, MPH, Chief of the Division of Gastroenterology and Hepatology at the University of North Carolina School of Medicine.  "Spray cryotherapy is well tolerated by patients, and an effective palliative treatment for these patients."

Dr. Shaheen is an internationally recognized clinician, educator and investigator and is an expert on Barrett's esophagus, reflux disease, and esophageal cancer. He has authored national guidelines for GERD, Barrett's esophagus, eosinophilic esophagitis, and the use of upper endoscopy, and serves as the director of the ACG (American College of Gastroenterology) Institute. 

About CSA Medical

CSA Medical, Inc. develops and manufactures a proprietary interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software driven device with specialty catheters that enable delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing. CSA manufactures and distributes this technology in the USA.  It is currently used to ablate benign (e.g. Barrett's Esophagus with high grade and/or low grade dysplasia) and malignant lesions.

To learn more about our technology, please visit www.csamedical.com. truFreeze is a registered trademark of CSA Medical, Inc.

For further information contact:
Teresa Prego, CSA Medical
+1-781-538-4793
[email protected]

SOURCE CSA Medical, Inc.

Related Links

http://www.csamedical.com